The inhibitor of BCL2, venetoclax, has proven beneficial in the treatment of chronic lymphocytic leukemia and AML, as well as in in vitro studies of hypodiploid samples of ALL characterized by a high expression of BCL2 [24]. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.